Flavivirus NS4B Mutations Attenuate Virulence
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current vaccine development for flaviviruses, such as West Nile virus, lacks effective attenuation methods to reduce virulence while maintaining immunogenicity, and existing mutations in nonstructural proteins like NS1 and NS4B do not adequately address the need for significantly attenuated strains.
Innovation Solution
Introduction of specific mutations in the NS4B protein, including cysteine residue deletions or substitutions, and abrogation of glycosylation sites in the NS1 protein to create attenuated flaviviral strains with reduced virulence and neuroinvasiveness, along with the development of chimeric viral genomes for enhanced attenuation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Object-affected harmful factors
If specific mutations are introduced in NS4B protein and glycosylation sites in NS1 protein to attenuate virulence, then virulence is reduced by 10,000-fold, but the complexity of vaccine development increases
Solution Approach 1:
The patent applies parameter changes by introducing specific mutations in the NS4B protein (amino acid positions 95-105) and abrogating glycosylation sites in the NS1 protein. These molecular-level parameter changes result in high-level attenuation of virulence (10,000-fold reduction) while maintaining immunogenicity, resolving the contradiction between reducing harmful effects and managing development complexity
Solution Approach 2:
The patent applies local quality by targeting specific local regions of the viral proteins - the central region of NS4B (amino acid positions 95-105) and glycosylation sites in NS1. By making localized modifications to specific amino acid residues rather than altering the entire virus, the patent achieves significant attenuation while keeping the vaccine development process manageable
2Object-affected harmful factors
If multiple mutations are introduced to achieve high-level attenuation, then virulence is significantly reduced, but the risk of revertant virulence increases
Solution Approach 1:
The patent applies segmentation by dividing the attenuation strategy into multiple independent mutation sites within the NS4B protein (amino acid positions 95-105) and separate glycosylation sites in the NS1 protein. This segmentation creates multiple genetic barriers that would need to revert simultaneously to restore virulence, significantly reducing the risk of revertant virulence while achieving high-level attenuation
Solution Approach 2:
The patent applies beforehand cushioning by pre-introducing multiple stabilizing mutations in the NS4B and NS1 proteins during vaccine development. These preemptive genetic modifications create a stable attenuated phenotype that is resistant to reversion, cushioning against the potential risk of revertant virulence before it can occur
3Object-affected harmful factors
If attenuated strains are developed with reduced neuroinvasiveness, then safety is improved, but the ability to induce protective immune response may be compromised
Solution Approach 1:
The patent applies parameter changes by making specific mutations in the NS4B protein central region (amino acid positions 95-105) and modifying glycosylation sites in NS1. These targeted parameter changes reduce neuroinvasiveness by over 1,000-fold while preserving the virus's ability to replicate sufficiently in tissue culture and induce protective immune responses, thus resolving the contradiction between safety and immunogenicity
Data Source
AI summary
Methods and compositions concerning mutant flaviviruses with reduced virulence. In some embodiments the invention concerns nucleotide sequences that encode mutant flaviviral proteins. Viruses comprising mutant NS1 and NS4B genes display reduced virulence are provided. In further aspects of the invention, flavivirus vaccine compositions such as West Nile virus vaccines are provided. In another embodiment the invention provides methods for vaccination against flavivirus infection.